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Abstract
Background: apogossypolone (ApoG2) is a novel derivate of gossypol. We previously have
reported that ApoG2 is a promising compound that kills nasopharyngeal carcinoma (NPC) cells by
inhibiting the antiapoptotic function of Bcl-2 proteins. However, some researchers demonstrate
that the antiproliferative effect of gossypol on breast cancer cells is mediated by induction of cell
cycle arrest. So this study was aimed to investigate the effect of ApoG2 on cell cycle proliferation
in NPC cells.
Results: We found that ApoG2 significantly suppressed the expression of c-Myc in NPC cells and
induced arrest at the DNA synthesis (S) phase in a large percentage of NPC cells. Immunoblot
analysis showed that expression of c-Myc protein was significantly downregulated by ApoG2 and
that the expression of c-Myc's downstream molecules cyclin D1 and cyclin E were inhibited
whereas p21 was induced. To further identify the cause-effect relationship between the
suppression of c-Myc signaling pathway and induction of cell cycle arrest, the expression of c-Myc
was interfered by siRNA. The results of cell cycle analysis showed that the downregulation of c-
Myc signaling pathway by siRNA interference could cause a significant arrest of NPC cell at S phase
of the cell cycle. In CNE-2 xenografts, ApoG2 significantly downregulated the expression of c-Myc
and suppressed tumor growth in vivo.
Conclusion: Our findings indicated that ApoG2 could potently disturb the proliferation of NPC
cells by suppressing c-Myc signaling pathway. This data suggested that the inhibitory effect of
ApoG2 on NPC cell cycle proliferation might contribute to its use in anticancer therapy.
Background
Nasopharyngeal carcinoma (NPC) is an epithelial squa-
mous cell carcinoma endemic in Southeast Asia and parts
of Mediterranean and northern Africa [1]. Radiotherapy
alone cures more than 90% of cases of stage I NPC; how-
ever, patients with advanced disease tend to experience
therapy failure. Several groups have shown that the 5-year
survival rate for concurrent chemotherapy and radiother-
apy is higher than that for radiotherapy alone in patients
with advanced disease [2,3]. Currently, cisplatin com-
bined with 5-fluorouracil is the first-line chemotherapeu-
tic regimen for NPC. Although this regimen has
manageable toxic effects and has yielded response rates
ranging from 65% to 75% [4], an urgent need for inpa-
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tient administration of chemotherapy has accelerated the
development of newer, more tolerable and potent plati-
num-based regimens. We previously showed that ApoG2
in particular could potently kill NPC cells and had a syn-
ergic effect with cisplatin to induce cell death [5]. In this
study, we further investigated the effect of ApoG2 on cell
cycle regulator proteins and cell cycle progression.
Gossypol and its derivates reportedly induce apoptosis by
inhibiting the antiapoptotic function of the Bcl-2 family
of proteins [5,6]. Also, authors have found cell cycle arrest
in gossypol-treated cells. Several cell cycle-related mole-
cules are involved in gossypol-induced cell cycle arrest.
For example, researchers have reported that gossypol-
induced cell death was coupled with upregulation of c-Fos
expression and biphasic c-Myc expression in rat spermato-
cytes [7]. Furthermore, transforming growth factor-β is
activated by gossypol in prostate cancer cells, and gossy-
pol upregulates p21 expression and downregulates cyclin
D1 and Rb expression in colon cancer cells [8,9]. Modifi-
cations of these cell cycle-related molecules result in can-
cer cell arrest at G0/G1 phase of the cell cycle. However,
Chang et al. found that gossypol did not affect cell cycle
progression or the p53 or p21/WAF signaling pathway in
A549 human alveolar lung cancer cells [10]. Different
oncogenic pathways are activated in different types of can-
cer, and treatment with gossypol may have various bio-
chemical and molecular impacts on different cancers with
specific biological behaviors.
NPC is associated with Epstein-Barr virus (EBV) infection
and genetic susceptibility. EBV-encoded latent membrane
protein 1 (LMP1) is a principal oncogene in cases of NPC;
it can activate a number of signaling pathways, including
nuclear factor-κb, mitogen-activated protein kinase, and
phosphoinositide 3-kinase [11]. Besides the LMP1-
induced oncogenic pathways, dysregulation of factors
such as p16, cyclin D1, and cyclin E leads to aberrations
in the cell cycle in NPC cells. Therefore, NPC has multiple
unique abnormalities that are potential targets for novel
treatments. In this study, we examined the effect of
ApoG2 on cell cycle distribution and the involved signal
pathways in NPC cells. The results demonstrated that
ApoG2 potently arrested cells at S phase of the cell cycle.
We also observed that suppression of the c-Myc signaling
pathway was responsible for the ApoG2-induced cell cycle
arrest.
Materials and methods
Cells, Drugs, and Reagents
Poorly differentiated human NPC cell lines CNE-2 and
HONE-1 were originally obtained from NPC patients and
maintained in our laboratory in RPMI-1640 (Gibco/BRL,
Gaithersburg, MD) supplemented with 10% heat-inacti-
vated fetal bovine serum (Thermo Scientific HyClone,
Logan, UT). Cells were incubated in a humidified 5% CO2
atmosphere at 37°C. ApoG2, which was supplied by
Dajun Yang (Ascenta Therapeutics Incorporation, Malvern,
Pennsylvania), was dissolved in pure dimethyl sulfoxide
(DMSO) at the stock concentration of 20 mmol/l and
stored at -20°C. 3-(4,5 dimethylthiazol-2-yl)-2, 5-diphe-
nyltetrazolium (MTT) were purchased from Sigma-
Aldrich (St. Louis, MO). In in vivo experiments, for intra-
peritoneal (i.p.) injection, ApoG2 was suspended in 0.5%
sodium carboxymethylcellulose and prepared on the day
of use.
MTT Assay
NPC cell viability was assessed using an MTT assay based
on mitochondrial conversion of MTT from soluble tetra-
zolium salt to an insoluble colored formazan precipitate,
which was dissolved in DMSO and quantitated using a
spectrophotometer (Thermo Multiskan MK3; Thermo
Fisher Scientific, Waltham. MA) with optical density (OD)
values [12]. NPC cells were plated in 96-well culture clus-
ters (Costar, Cambridge, MA) at a density of 15,000 to
25,000 cells/ml. Serial dilutions of ApoG2 were prepared
from a stock solution to the desired concentrations. The
final DMSO concentration was less than 0.1% (v/v). All
experimental concentrations of ApoG2 were prepared in
triplicate. Cells were treated with ApoG2 for 24, 48 and 72
h. Before termination of treatment, cells were incubated
with 10 μl of 10 mg/ml MTT for 4 h. Then MTT and
medium were depleted, and 100 μl of DMSO was added
to the plates. The percent absorbance of Apog2-treated
cells relative to the control (DMSO treated cells, DMSO
concentration was less than 0.1%) was plotted as a linear
function of the drug concentration. The antiproliferative
effect of ApoG2 on NPC cells was measured as the percent
of viable cells relative to the control using the equation
100% × ODT/ODC, in which ODT is the mean OD value of
the ApoG2-treated treated samples and ODC is the mean
OD value of the control samples. The 50% inhibitory con-
centration of ApoG2 was defined as the concentration of
the drug required to achieve 50% growth inhibition rela-
tive to control populations.
Cell Cycle Analysis
Untreated control and ApoG2-treated CNE-2 cells were
harvested, washed twice with phosphate-buffered saline
(PBS), and fixed dropwise with 2 ml of 70% ice-cold eth-
anol. After cells fixed overnight at 4°C, cells were then
washed twice with PBS; cells were then incubated in
RNase (20 μg/ml) at 37°C for 30 min to avoid staining
the RNA. Next, the cells were washed once with PBS; PI
was added to samples at a final concentration of 15 μmol/
l, and after 5 min of incubation, the cells were analyzed
using flow cytometry (Beckman Coulter, Fullerton, CA).
The percentages of the nuclei in CNE-2 cells at each phase
of the cell cycle (G1, S, G2/M) were calculated using theJournal of Translational Medicine 2009, 7:74 http://www.translational-medicine.com/content/7/1/74
Page 3 of 11
(page number not for citation purposes)
MultiCycle software program (Phoenix Flow Systems, San
Diego, CA).
Immunoblot Analysis
Protein analysis using immunoblotting and immunopre-
cipitation was performed with primary antibodies against
p53 (sc-126; Santa Cruz Biotechnology, Santa Cruz, CA),
p21 (sc-6246; Santa Cruz Biotechnology), c-Myc (sc-42;
Santa Cruz Biotechnology), cyclin E (sc-481; Santa Cruz
Biotechnology), cyclin D1 (sc-8396; Santa Cruz Biotech-
nology), and actin (clone AC-15; Sigma-Aldrich) as
described previously [13]. Total cell lysates were har-
vested, electrophoresed using 12% sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis, and transferred to
polyvinylidene difluoride membranes (Roche, Grenzach-
erstrasse, Basel, Switzerland). Immunoblotting was per-
formed using the primary antibodies described above
followed by detection of protein expression using second-
ary antibodies conjugated with horseradish peroxidase
(Cell Signaling Technology, Danvers, MA), and blots were
developed using ECL chemiluminescent reagent (Cell Sig-
naling Technology).
RNA Interference
Transient small interfering RNA (siRNA) transfection was
performed using Lipofectamine 2000 (Invitrogen, San
Diego, CA) and 50 nM siRNA oligonucleotides. Commer-
cially purchased siRNAs (Ribobio, Guangzhou, People's
Republic of China) were scrambled (nontargeting), glyc-
eraldehyde-3-phosphate dehydrogenase siRNA, and c-
Myc siRNA. The three independent oligonucleotides
designed for the c-Myc siRNA sequences were 5'-
CAGAAATGTCCTGAGCAAT-3', 5'-AAGGTCAGAGTCT-
GGATCACC-3', and 5'-AAGGACTATCCTGCTGCCAAG-
3'. The siRNA duplexes were introduced into CNE-2 cells
according to the siRNA manufacturer's protocol. After
transfection with siRNA for 48 h, cells were harvested for
immunoblots and cell cycle analysis. The scrambled
siRNA construct was used as a negative control.
In vivo treatment and immunohistochemistry assay
Four-week-old athymic nude (nu/nu) mice obtained from
the Animal Center of Southern Medical University
(Guangdong, China) received subcutaneous injection of 1
× 107 CNE-2 cells in each axillary area. When subcutane-
ous tumors developed to more than 1,500 mg, mice were
euthanized and tumors were dissected and mechanically
dissociated into equal pieces to be transplanted into the
flank areas of a new group of mice. When xenograft
tumors became palpable (about 0.1 mm3), mice were ran-
domly divided into control (0.5% sodium carboxymeth-
ylcellulose solution) and ApoG2 (120 mg/kg of body
weight given by intraperitoneal injection daily) groups.
Each group contained 8 mice, and there was no difference
in tumor size between groups. Based on our lab's policy,
when xenograft tumors developed to more than 1,000
mg, mice were euthanized and tumors were dissected and
weighed. Immunohistochemical analysis was performed
on tissue-sample sections of CNE-2 xenografts obtained
from control and ApoG2. All samples were stained with
hematoxylin and eosin and microscopically examined to
confirm the CNE-2 cell origin. Sections were then stained
with c-Myc (#; Santa Cruz) at 4°C overnight and then vis-
ualized using diaminobenzidine (DAB) (DAKO Liquid
DAB, Dako, Carpinteria, CA) as peroxidase substrates.
Statistical analysis
All analyses to compare the significance of measured lev-
els were completed using the unpaired t-test by SPSS 16.0
software.
Results
ApoG2 Inhibits Cell Proliferation of NPC cells
Our previous work demonstrated that ApoG2 (Fig. 1A, the
chemical structure of ApoG2) could significantly kill NPC
cells and suppress the growth of NPC xenografts in nude
mice. In this study, we reevaluated the antiproliferative
effect of ApoG2 on CNE-2 cells using an MTT assay. We
treated CNE-2 cells with 5, 10 and 20 μM ApoG2 for 24,
48 and 72 h. This treatment resulted in dose- and time-
dependent inhibition of cell proliferation (Fig. 1B). At 10
and 20 μM, ApoG2 inhibited about 60% and 90% of the
cell growth, respectively, at 72 h.
Moreover, among four NPC cell lines C666-1 (EBV
infected), CNE-1 (highly differentiated), CNE-2 (poorly
differentiated) and HONE-1 (poorly differentiated),
ApoG2 treatment resulted in a tremendous inhibition of
cell proliferation in C666-1, CNE-1 and CNE-2 NPC cell
lines. At 10 μM, ApoG2 inhibited more than 60% of the
cell growth of C666-1, CNE-1 and CNE-2 cells at 72 h. In
contrast, only about 30% of HONE-1 cell proliferation
was inhibited by 10 μM ApoG2 treatment for 72 h.
AapoG2 Treatment Induces NPC Cells Arresting in S Phase 
of Cell Cycle
Gossypol reportedly induces cell cycle arrest in prostate
cancer cells and colon cancer cells [8,9]. To determine
whether ApoG2 could also induce cell cycle arrest in NPC
cells, we performed a cell cycle analysis using flow cytom-
etry. The results showed the same with our previous work
[5] that, at 48 h after treatment, ApoG2 did not induce
obvious cell apoptosis in NPC cells and little cells were
accumulated in sub-G1 phase. Instead, ApoG2 induced
cell cycle arrest at the DNA synthesis (S) phase in a large
percentage of NPC cells at this time. More than 60% of
C666-1, CNE-1 and CNE-2 cells were arrested at S phase
at 48 h after exposure to 5 and 10 μM ApoG2, whereas
only 34%, 39% and 35%, respectively, of untreated C666-Journal of Translational Medicine 2009, 7:74 http://www.translational-medicine.com/content/7/1/74
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ApoG2 and its inhibitory effect on CNE-2 cell proliferation Figure 1
ApoG2 and its inhibitory effect on CNE-2 cell proliferation. (A) The chemical structure of ApoG2. (B) Effect of 
ApoG2 on NPC cell survival. Cells were exposed to 5, 10, and 20 μM ApoG2 for 24, 48, and 72 h. Compared to control cells 
(treated with 0.1% DMSO), percentage of viable cells in treated samples was measured using an MTT assay (mean ± standard 
deviation for three experiments). (C) The inhibitory effect of ApoG2 on four NPC cell lines (HONE-1, CNE-2, CNE-1 and 
C666-1) was compared after 72-hr treatment. Points, average of three experiments; bars, SD.Journal of Translational Medicine 2009, 7:74 http://www.translational-medicine.com/content/7/1/74
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1, CNE-1 and CNE-2 cells were arrested at S phase (Fig.
2A–C).
Because we observed that another NPC cell line, HONE-1,
was much less sensitive to ApoG2 treatment and exhibited
a much higher 50% inhibitory concentration value of
ApoG2 (more than 10-fold) than C666-1, CNE-1 and
CNE-2 cells (data not shown), we assessed the effect of
ApoG2 on the cell cycle in this cell line. Treatment with 10
μM ApoG2 induced about 60% HONE-1 cells arresting at
S phase (Fig. 2D); in comparison, only 34% of untreated
HONE-1 cells were arrested at S phase of the cell cycle.
These data implied that ApoG2-induced cell cycle arrest is
not correlated with the sensitivity of cells to ApoG2,
because in both ApoG2-sensitive NPC cells and ApoG2-
insensitive HONE-1 cells, ApoG2 treatment could result
in significant cell cycle arrest. These data also implied that
ApoG2-induced cell cycle arrest was not caused the inhi-
bition of Bcl-2 proteins and other molecular mechanisms
might be involved in ApoG2-induced cell cycle arrest in
NPC cells.
Downregulation of c-Myc Expression Leads to Cell Cycle 
Arrest by ApoG2 in NPC cells
Because researchers have reported that cell cycle-regulat-
ing molecules, such as p21, p53, and TGF-β1, play roles in
gossypol-induced cell cycle arrest [9,14], we hypothesized
that ApoG2 can also modify some cell cycle regulators,
resulting in cell cycle arrest in NPC cells. Consistent with
our hypothesis, treatment with 10 μM ApoG2 signifi-
cantly decreased the level of c-Myc protein expression at
24 h in CNE-2 cells (Fig. 3A). Moreover, expression of p21
protein was upregulated as early as 24 h and gradually
returned to low level at 72 h since most of the CNE-2 cells
were dead at this time (Fig. 3B); unlike p21, expression of
both cyclin D1 and cyclin E were downregulated follow-
ing the degradation of c-Myc. We observed no changes in
p53 protein expression (Fig. 3B). Similar changes in the c-
Myc pathway were also detected in ApoG2-treated HONE-
1 cells (Fig. 3C), which was in agreement with the results
of cell cycle analysis that ApoG2 induced cell cycle arrest
in both sensitive CNE-2 cells and insensitive HONE-1
cells.
Downregulation of c-Myc Expression by siRNA Leads to 
Cell Cycle Arrest at S Phase in CNE-2 Cells
Authors have reported that the oncoprotein c-Myc regu-
lates the expression of p21 and cyclins, increases cyclin D-
CDK4 activity, and facilitates cell cycle progression [15].
Also, Fan et al. found that upregulated expression of c-Myc
protein in NPC cells contributed to unrestricted cell pro-
liferation, metastasis, and tumor progression [16]. In our
study, the immunoblots data indicated that suppression
of the c-Myc pathway might be responsible for ApoG2-
induced cell cycle arrest in NPC cells. To test this hypoth-
esis, we used three siRNA oligonucleotides (Ribobio,
Guangzhou, China) to knock down c-Myc protein in
CNE-2 cells. As shown in fig. 4A, all these three oligonu-
cleotides significantly suppressed the expression of c-Myc
protein; the reduction in c-Myc expression led to upregu-
lation of p21 expression and downregulation of cyclin D
expression. Cell cycle analysis showed that incubation
with scrambled siRNA resulted in a significantly lower
CNE-2 cell population arrested at S phase than did incu-
bation with c-Myc siRNA (Fig. 4B and 4C). Compared to
srambled siRNA, c-Myc siRNAs induced conspicuous
increasing of cells in S phase in CNE-2 cells at 48 h (Fig.
4D). Based on these results, we suggested that suppression
of the c-Myc pathway by ApoG2 leads directly to cell cycle
arrest in NPC cells.
ApoG2 inhibites c-Myc expression level in CNE-2
xenografts in nude miceTo assess the effect of ApoG2 on
c-Myc expression in vivo, we used the CNE-2 xenografts
nude mice model. When control xenografts developed to
more than 1,000 mg, all mice were euthanized and
tumors were dissected, weighed and fixed for immuno-
chemistry assay. As shown in fig. 5A and 5B, compared to
NS (normal saline) treatment group, ApoG2 treatment
provoked a significant reduction in c-Myc expression level
in CNE-2 xenografts. Antitumor activities of ApoG2 (120
mg/kg i.p. injection once every three days) against CNE-2-
bearing nude mice was measured by weighing the weight
of CNE-2 xenografts (Fig. 5C). As shown in fig. 5D, com-
pared to control treatment, ApoG2 could significantly
inhibit tumor weight in CNE-2 xenografts (p < 0.001).
Discussion
ApoG2 is the oxidation product of gossypol and has two
aromatic hydrocarbon quinone groups. Authors have
reported that aromatic hydrocarbon quinone stimulates
ROS production in hepatic cells [17]. As we known, ele-
vated ROS levels may damage cellular DNA, inducing gen-
eration of oxidized bases, DNA strand breaks, and stop of
DNA replication, in ApoG2-treated CNE-2 cells. Recent
studies provided evidence that multiple chemopreventive
agents can cause generation of ROS to trigger signal trans-
duction, culminating in cell cycle arrest and/or apoptosis
[18,19]. However, Van Poznak et al. and Zhang et al. sug-
gested that gossypol-induced cell cycle arrest is associated
with alterations of p21, cyclin D1, and p53 and showed
that p21 is the first target of gossypol to inhibit cell growth
in vivo [9,20]. Our data indicated that ApoG2 induced
massive cells arrest at S phase of the cell cycle not only in
ApoG2-sensitive NPC cells but also in ApoG2-insensitive
HONE-1 cells (Fig. 3). Results of signaling pathway anal-
ysis showed that downregulation of c-Myc protein expres-
sion was the major upstream event in ApoG2-induced cell
cycle arrest in NPC cells (Fig. 4). Basically, the effect of c-
Myc on cell cycle is to drive quiescent cells into the cellJournal of Translational Medicine 2009, 7:74 http://www.translational-medicine.com/content/7/1/74
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Arrest of NPC cells at S phase of the cell cycle by treatment with ApoG2 Figure 2
Arrest of NPC cells at S phase of the cell cycle by treatment with ApoG2. Arrest of NPC cells at S phase by ApoG2. 
C666-1 (A), CNE-1 (B), CNE-2 (C) and HONE-1 (D) cells were treated with 5 and 10 μM ApoG2 for 48 h. DNA cell cycle 
analysis was performed using PI staining and flow cytometry. Each histogram is representative of three experiments. (E) Cell 
cycle analysis showed that ApoG2 treatment induced a conspicuous increasing of cells in S phase in four NPC cell line at 48 h. 
Bar heights, average of three independent experiments; bars, SD.Journal of Translational Medicine 2009, 7:74 http://www.translational-medicine.com/content/7/1/74
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cycle, and shortening G1 and promoting S phase entry
thereby. The down-regulation of c-Myc should cause a
preferential G1/S arrest rather than S arrest. However, in
NPC cells, although p53 was highly expressed and its
expression was never downregulated by ApoG2 in this
study, p53 was mutated and functionally impaired by
Epstein-Barr virus nuclear antigen 5 and deltaN-p63 in
NPC cells [21,22]. In this scenario of malfunction of G1-
S checkpoint p53, c-Myc was a main factor accounting for
ApoG2-induced S phase arrest. P21 and cyclins were fol-
lowed by downregulation of c-Myc expression.
c-Myc is not only a central regulator of cell proliferation
but also induces cells to undergo apoptosis, unless spe-
cific signals provided by oncogenes block the apoptosis
pathway [23]. Notably, NPC cells consistently harbor EBV
DNA and express EBV proteins, LMP1 and BARF1; these
proteins stimulate oncogenic antiapoptotic Bcl-2 proteins
to protect host cancer cells from apoptosis [24-27].
ApoG2 is a potent inhibitor of antiapoptotic Bcl-2 pro-
teins and its treatment could remove the protective effect
of Bcl-2 proteins and facilitate apoptosis. In this case,
downregulation of c-Myc expression by ApoG2 on one
hand could let cells away from c-Myc-induced apoptosis
and on other hand led to cell cycle arrest. However, by
inhibiting Bcl-2 proteins, ApoG2 still helped release pro-
apoptotic proteins, such as Bax and Bak, and irreversibly
damaged mitochondria and induced cell apoptotic [5].
Treatment with ApoG2 induces alterations in the expression of c-Myc, p21, and cyclins Figure 3
Treatment with ApoG2 induces alterations in the expression of c-Myc, p21, and cyclins. (A) The effect of ApoG2 
on the expression of c-Myc. CNE-2 cells were incubated with 10 μM ApoG2 for 24 to 72 h, and cell lysates were analyzed 
using immunoblotting. (B) The effect of ApoG2 on the expression of molecules downstream from c-Myc. After treatment with 
ApoG2, CNE-2 cell lysates were analyzed using immunoblotting with anti-p21, -cyclin D1, -cyclin E, and -p53 antibodies. (C) 
The effect of ApoG2 on cell cycle-regulatory molecules in HONE-1 cells. Cells were treated with 10 μM ApoG2 for 24 to 72 
h, and cell lysates were analyzed using immunoblotting.Journal of Translational Medicine 2009, 7:74 http://www.translational-medicine.com/content/7/1/74
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The effect c-Myc siRNA transfection on c-Myc downstream molecules and cell cycle distribution Figure 4
The effect c-Myc siRNA transfection on c-Myc downstream molecules and cell cycle distribution. (A) Compari-
son of the effect of c-Myc siRNA and scrambled (nontargeting) siRNA on the expression of c-Myc downstream molecules. 
Transfection of CNE-2 cells with c-Myc or scrambled (nontargeting) siRNA for 48 h. Cells were then subjected to Western 
blotting using anti-c-Myc, -cyclin D1, -p21, and -p53 antibodies as described in Materials and Methods. Comparison of the effect 
of scrambled (nontargeting) siRNA (B) and c-Myc siRNA (C) on cell cycle distribution of CNE-2 cells using PI staining and 
flow cytometry. Each histogram is representative of three experiments. (D) Analysis of cell cycle distributions showed that, 
compared to srambled siRNA, c-Myc siRNA induced a conspicuous increasing of cells in S phase in CNE-2 cells at 48 h. Bar 
heights, average of three independent experiments; bars, SD.Journal of Translational Medicine 2009, 7:74 http://www.translational-medicine.com/content/7/1/74
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Analysis of the impact of ApoG2 in vivo on c-Myc expression and tumor growth in CNE-2 xenografts Figure 5
Analysis of the impact of ApoG2 in vivo on c-Myc expression and tumor growth in CNE-2 xenografts. The tumor 
tissues from ApoG2 (120 mg/kg intraperitoneal injection daily) treatment were obtained at the end of 12 days of treatment. 
Immunochemistry analysis of c-Myc expression in CNE-2 xenograft tumor sections after NS treatment (A) or ApoG2 treat-
ment (B), magnification, × 80. (C) Photographs of CNE-2 xenografts from NS treatment and ApoG2 treatment groups. When 
all tumors of the control group exceeded 1 g in weight, the animal experiment was terminated and mice were killed. The 
tumors were taken out for weighing and comparing the effect of ApoG2 on tumors. (D) Antitumor acitivity of ApoG2 in CNE-
2 xenograft-bearing nude mice. Compared to control (NS treatment) mice, ApoG2 treatment greatly suppressed tumor 
weight. Bar heights, average weight of eight CNE-2 xenograft tumors; bars, SD.Journal of Translational Medicine 2009, 7:74 http://www.translational-medicine.com/content/7/1/74
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Gossypol is clinically used in China to treat adenomyosis
and hysteromyoma because of its ability to inhibit estro-
gen and progesterone by competitively binding to the
estrogen receptor and progesterone receptor [28]. c-Myc is
a well-established target of estrogen action and plays a
role in controlling cell cycle progression. Anti-estrogen
treatment is reported to be able to cause an acute decrease
in c-Myc expression, a subsequent decline in cyclin D1
expression, and, ultimately, inhibition of DNA synthesis
and arrest of cells in a quiescent state [29]. Estrogen recep-
tor and progesterone receptor are known to be highly
expressed in NPC cells, and their expression is considered
a sign of distant metastasis and a poor prognosis [30].
Based on our findings, we suggest that ApoG2-induced
cell cycle arrest is dependent on ApoG2's downregulation
of c-Myc expression. Use of ApoG2 to treat NPC may sup-
press the activity of estrogen and progesterone and reduce
the incidence of distant metastasis and local relapse.
The concept of targeted biological therapy for cancer has
emerged over the past decade. Clinical trials studying the
efficacy and tolerability of these targeted agents has
shown that most tumors depend on more than one sign-
aling pathway for their growth and survival. Therefore,
investigators pursue different strategies to inhibit multiple
signaling pathways by developing multitargeted agents
[31]. The recent U.S. Food and Drug Administration
approval of sorafenib and sunitinib, which target vascular
endothelial growth factor receptor, platelet-derived
growth factor receptor, FLT-3, and c-Kit, marks the use of
a new generation of multitarget anticancer drugs [32]. Our
study show that ApoG2 is one such multitarget agent that
targets both the antiapoptotic and cell cycle progression
pathway in NPC cells by blocking antiapoptotic Bcl-2 pro-
teins and the c-Myc oncogenic pathway. These findings
provide an entirely new concept for the use of ApoG2 in
cancer therapy.
Conclusion
Our findings indicated that ApoG2 can potently disturb
the proliferation of NPC cells by suppressed c-Myc signal-
ing pathway. This data suggested that the inhibitory effect
of ApoG2 on NPC cell cycle proliferation might contrib-
ute to its use in anticancer therapy.
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